Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stem Cell Transplantation, Hematopoietic Clear all
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Stem Cell Transplant for CLL

NCT01629511
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Richter Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Filgrastim, Gemcitabine, Methotrexate, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

NCT00002819
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, paclitaxel, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
64
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00002945
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

NCT00003101
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, busulfan, lomustine, procarbazine hydrochloride, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
5
States / cities
Birmingham, Alabama • Stanford, California • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jul 23, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

NCT02782546
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

NCT03147742
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

NCT00242996
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, sargramostim, carmustine, cyclophosphamide, etoposide, adjuvant therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

NCT05167370
View directory record Official record
Conditions
Solid Tumors, Brain Tumors
Interventions
Amifostine
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting Phase 2 Interventional

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

NCT04356469
View directory record Official record
Conditions
Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Haploidentical Hematopoietic Cell Transplantation
Biological
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

NCT05907746
View directory record Official record
Conditions
GATA2, Immunodeficiency
Interventions
Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide, Total Body Irradiation, Hematopoietic Cell Transplant, Briquilimab, Cyclophosphamide, Fludarabine, Bone Marrow Biopsy, Bone Marrow Aspirate, 2D echo, EKG, PFT's, CT scan of chest, abdomen and pelvis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
6 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation

NCT00760227
View directory record Official record
Conditions
Bone Marrow, Stem Cell Transplant
Interventions
Massage Therapy, Humor Therapy, Relaxation Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
3
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

NCT03032783
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Hematopoietic Stem Cell Transplantation
Radiation · Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadephia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 23, 2026, 10:27 PM EDT
Active, not recruiting Phase 1 Interventional

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

NCT03531736
View directory record Official record
Conditions
Myeloid Diseases
Interventions
Antithymocyte globulin (Rabbit), fludarabine, total body irradiation, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Middletown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting Early Phase 1 Interventional

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting No phase listed Observational

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

NCT02677064
View directory record Official record
Conditions
Acute Leukemia, Newly Diagnosed, Relapsed
Interventions
assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Hartford, Connecticut • New York, New York • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

NCT00003406
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jul 23, 2026, 10:27 PM EDT
Completed No phase listed Observational

Iron Overload in Stem Cell Transplant Recipients

NCT00806715
View directory record Official record
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

NCT01682226
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Lymphoma
Interventions
CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
Device · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00004085
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 23, 2026, 10:27 PM EDT